PONY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. Price is weakening (down ~3.1% today and below the nearby S1 support area), momentum is still deteriorating (MACD histogram negative and expanding), and Intellectia signals show no tactical “buy-now” edge. While news flow and Street targets skew optimistic longer-term, the near-term tape suggests you’re more likely to sit through additional chop/downside before a cleaner bounce setup appears.
Trend/momentum: Bearish-to-neutral. MACD histogram at -0.206 is below zero and negatively expanding, indicating downside momentum is still building.
RSI: RSI(6) ~28.1, which is effectively oversold/near-oversold and can support a reflex bounce, but oversold can persist in downtrends.
Levels: Pivot 15.732 is well above current 14.05 (price below pivot = weak). Key supports: S1 14.544 (currently below it, a negative sign) and S2 13.81 (next downside level to watch). Resistances: 16.92 then 17.654.
Moving averages: Converging MAs suggests the stock may be trying to base, but it’s not yet confirming an uptrend.
Near-term pattern stats provided: Similar-pattern outlook implies ~-0.43% next day, ~+0.11% next week, and ~+7.69% next month—more consistent with near-term churn followed by potential recovery, not an immediate clean breakout.
Intellectia Proprietary Trading Signals
on a strategic partnership with Beijing ATBB to accelerate Robotaxi commercialization in tier-1 cities; plan to expand fleet from 1,159 to >3,000 vehicles by end of
This is a clear scale-up narrative and can support multi-month sentiment.
before a durable bounce.
Latest quarter provided: 2025/Q3.
Growth: Revenue was $25.44M, shown as 0.00% YoY change (flat in the provided data).
Profitability: Net income was -$61.315M (still deeply negative). EPS -0.16.
Margins: Gross margin 18.35% (positive but not yet translating into profitability).
Takeaway: Operationally still in an investment/loss phase; the fundamental story is execution-and-scale driven rather than current earnings power, which tends to align better with longer holding periods than an impatient, immediate-entry approach.
Recent trend: Coverage has recently been initiated/updated with a split tone—Macquarie initiated Outperform with a high $29 target (bullish on commercialization and cost declines into 2026), while Barclays initiated Equal Weight with a $15 target (more cautious on industry challenges). Citi kept Buy but cut target to $24.50 from $29 due to dilution concerns tied to the Hong Kong listing.
Wall Street pros: Clear long-term upside case if robotaxi commercialization scales (fleet growth, potential cost declines, first-mover positioning).
Wall Street cons: Dilution/financing overhang, commercialization timeline uncertainty, and near-term economics/industry headwinds.
Influential/political trading: No recent congress trading data available; insiders reported neutral.
